These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 23812204

  • 21. Diagnosing aceruloplasminemia: navigating through red herrings.
    Kharel Z, Kharel H, Phatak PD.
    Ann Hematol; 2024 Jun; 103(6):2173-2176. PubMed ID: 38637332
    [Abstract] [Full Text] [Related]

  • 22. Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia.
    Pelucchi S, Mariani R, Ravasi G, Pelloni I, Marano M, Tremolizzo L, Alessio M, Piperno A.
    Parkinsonism Relat Disord; 2018 Jun; 51():36-42. PubMed ID: 29503155
    [Abstract] [Full Text] [Related]

  • 23. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
    Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR.
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):467-70. PubMed ID: 17911185
    [Abstract] [Full Text] [Related]

  • 24. [Aceruloplasminemia, a rare condition not to be overlooked].
    Lobbes H, Reynaud Q, Mainbourg S, Lega JC, Durieu I, Durupt S.
    Rev Med Interne; 2020 Nov; 41(11):769-775. PubMed ID: 32682623
    [Abstract] [Full Text] [Related]

  • 25. Central nervous system involvement in a rare genetic iron overload disorder.
    Bethlehem C, van Harten B, Hoogendoorn M.
    Neth J Med; 2010 Oct; 68(10):316-8. PubMed ID: 21071777
    [Abstract] [Full Text] [Related]

  • 26. Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.
    Poli L, Alberici A, Buzzi P, Marchina E, Lanari A, Arosio C, Ciccone A, Semeraro F, Gasparotti R, Padovani A, Borroni B.
    Neurol Sci; 2017 Feb; 38(2):357-360. PubMed ID: 27817091
    [Abstract] [Full Text] [Related]

  • 27. Aceruloplasminemia.
    Kono S.
    Curr Drug Targets; 2012 Aug; 13(9):1190-9. PubMed ID: 22515740
    [Abstract] [Full Text] [Related]

  • 28. Movement disorders and brain iron overload in a new subtype of aceruloplasminemia.
    Melgari JM, Marano M, Quattrocchi CC, Piperno A, Arosio C, Frontali M, Nuovo S, Siotto M, Salomone G, Altavilla R, di Biase L, Scrascia F, Squitti R, Vernieri F.
    Parkinsonism Relat Disord; 2015 Jun; 21(6):658-60. PubMed ID: 25864092
    [No Abstract] [Full Text] [Related]

  • 29. Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
    Bove F, Fasano A.
    Neurology; 2015 Sep 22; 85(12):1085-6. PubMed ID: 26311749
    [No Abstract] [Full Text] [Related]

  • 30. [Deferasirox--a new oral iron chelator--review].
    Wang T, Gao C, Chen BA.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct 22; 18(5):1359-64. PubMed ID: 21129294
    [Abstract] [Full Text] [Related]

  • 31. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Pharmacoeconomics; 2007 Oct 22; 25(4):329-42. PubMed ID: 17402805
    [Abstract] [Full Text] [Related]

  • 32. Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series.
    Vroegindeweij LH, van der Beek EH, Boon AJ, Hoogendoorn M, Kievit JA, Wilson JH, Langendonk JG.
    Diabet Med; 2015 Aug 22; 32(8):993-1000. PubMed ID: 25661792
    [Abstract] [Full Text] [Related]

  • 33. Deferasirox therapy in children with Fanconi aplastic anemia.
    Tunç B, Tavil B, Karakurt N, Yarali N, Azik FM, Kara A, Culha V, Ozkasap S.
    J Pediatr Hematol Oncol; 2012 May 22; 34(4):247-51. PubMed ID: 22510772
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Aceruloplasminemia With Psychomotor Excitement and Neurological Sign Was Improved by Minocycline (Case Report).
    Hayashida M, Hashioka S, Miki H, Nagahama M, Wake R, Miyaoka T, Horiguchi J.
    Medicine (Baltimore); 2016 May 22; 95(19):e3594. PubMed ID: 27175663
    [Abstract] [Full Text] [Related]

  • 39. Reversible retinopathy associated with oral deferasirox therapy.
    Walia HS, Yan J.
    BMJ Case Rep; 2013 Jul 17; 2013():. PubMed ID: 23867877
    [Abstract] [Full Text] [Related]

  • 40. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
    Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, Campbell CM, Subramaniam VN, Crawford DH.
    J Gastroenterol Hepatol; 2015 Mar 17; 30(3):638-45. PubMed ID: 25168203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.